New‐onset prediabetes/diabetes worsens overall survival in patients with cancer: A real‐world retrospective cohort study
Main finding · Overall survivalResult — go to the resultHR for death (worse overall survival) 2.97 95% CI 2.48–3.55Authors' conclusion
Improving clinical practice guidelines for appropriate hyperglycemia monitoring and management, especially in the first 3 years after cancer diagnosis, may improve cancer survival. Early intervention with non-insulin antihyperglycemic medications for control of new-onset prediabetes/diabetes may be crucial in preventing the need for insulin prescription and worsening of survival.
Study context
- Population
- Solid tumour patients at the Huntsman Cancer Institute, a comprehensive cancer centre in Utah, USA
- Participants
- 7,300 patients
- Exposure
- New-onset prediabetes/diabetes after cancer diagnosis vs no prediabetes/diabetes
- Outcome
- Overall survival
Methodological detailselectronic health record data, single-centre
- Electronic health record data
- Single-centre
Main finding
As reported in the abstract
HR for death (worse overall survival)
2.97
95% CI 2.48–3.55
New-onset prediabetes/diabetesvs Without prediabetes/diabetes
HR for death (worse overall survival) 2.97 (95% CI 2.48–3.55)
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | |
|---|---|---|
| Overall survival by antihyperglycemic prescription, vs without prediabetes/diabetesNot prescribed antihyperglycemic medicationsvs Without prediabetes/diabetes | HR for death (poorer survival) 2.52 (95% CI 2.17–2.93) | |
| Overall survival by antihyperglycemic prescription, vs without prediabetes/diabetesPrescribed antihyperglycemic medications (n = 665)vs Without prediabetes/diabetes | HR for death (poorer survival) 1.70 (95% CI 1.40–2.06) | |
| Overall survival by antihyperglycemic medicationEver metforminvs Other non-insulin antihyperglycemic medications | HR for death (better survival with metformin) 0.32 (95% CI 0.15–0.66) | |
| Overall survival by antihyperglycemic medicationEver insulinvs Non-insulin antihyperglycemic medications | HR for death (worse survival with insulin) 1.67 (95% CI 1.16–2.42) | |
| 0.10.31310Ratio (log scale) |
Development of prediabetes/diabetes after cancer diagnosis · mean time-to-onset = 2.6 years
- Developed prediabetes/diabetes after cancer diagnosis
- 23%
Original publication
New‐onset prediabetes/diabetes worsens overall survival in patients with cancer: A real‐world retrospective cohort study. Diabetes Obes Metab. Published 24 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →